Logo image of BFRI

BIOFRONTERA INC (BFRI) Stock Fundamental Analysis

NASDAQ:BFRI - Nasdaq - US09077D2099 - Common Stock - Currency: USD

0.6398  -0.03 (-4.19%)

After market: 0.64 +0 (+0.03%)

Fundamental Rating

2

Overall BFRI gets a fundamental rating of 2 out of 10. We evaluated BFRI against 198 industry peers in the Pharmaceuticals industry. BFRI may be in some trouble as it scores bad on both profitability and health. BFRI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BFRI has reported negative net income.
In the past year BFRI has reported a negative cash flow from operations.
BFRI had negative earnings in each of the past 5 years.
In the past 5 years BFRI always reported negative operating cash flow.
BFRI Yearly Net Income VS EBIT VS OCF VS FCFBFRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

BFRI has a worse Return On Assets (-80.35%) than 71.72% of its industry peers.
With a Return On Equity value of -400.61%, BFRI is not doing good in the industry: 77.27% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -80.35%
ROE -400.61%
ROIC N/A
ROA(3y)-51.23%
ROA(5y)-54.01%
ROE(3y)-274.43%
ROE(5y)-268.87%
ROIC(3y)N/A
ROIC(5y)N/A
BFRI Yearly ROA, ROE, ROICBFRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

With a decent Gross Margin value of 50.14%, BFRI is doing good in the industry, outperforming 62.12% of the companies in the same industry.
BFRI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BFRI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y-0.95%
BFRI Yearly Profit, Operating, Gross MarginsBFRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

BFRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BFRI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BFRI has more shares outstanding
BFRI has a worse debt/assets ratio than last year.
BFRI Yearly Shares OutstandingBFRI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
BFRI Yearly Total Debt VS Total AssetsBFRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -7.65, we must say that BFRI is in the distress zone and has some risk of bankruptcy.
BFRI has a Altman-Z score of -7.65. This is in the lower half of the industry: BFRI underperforms 67.68% of its industry peers.
BFRI has a Debt/Equity ratio of 0.92. This is a neutral value indicating BFRI is somewhat dependend on debt financing.
BFRI has a worse Debt to Equity ratio (0.92) than 69.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Altman-Z -7.65
ROIC/WACCN/A
WACC21.69%
BFRI Yearly LT Debt VS Equity VS FCFBFRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 1.72 indicates that BFRI should not have too much problems paying its short term obligations.
BFRI has a Current ratio of 1.72. This is in the lower half of the industry: BFRI underperforms 63.64% of its industry peers.
BFRI has a Quick Ratio of 1.17. This is a normal value and indicates that BFRI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of BFRI (1.17) is worse than 69.70% of its industry peers.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.17
BFRI Yearly Current Assets VS Current LiabilitesBFRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

BFRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.41%, which is quite impressive.
BFRI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.53%.
The Revenue has been growing slightly by 7.35% on average over the past years.
EPS 1Y (TTM)78.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.11%
Revenue 1Y (TTM)9.53%
Revenue growth 3Y15.69%
Revenue growth 5Y7.35%
Sales Q2Q%18.53%

3.2 Future

The Earnings Per Share is expected to grow by 27.72% on average over the next years. This is a very strong growth
Based on estimates for the next years, BFRI will show a very strong growth in Revenue. The Revenue will grow by 23.53% on average per year.
EPS Next Y81.24%
EPS Next 2Y39.55%
EPS Next 3Y27.72%
EPS Next 5YN/A
Revenue Next Year10.36%
Revenue Next 2Y15.16%
Revenue Next 3Y22.03%
Revenue Next 5Y23.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BFRI Yearly Revenue VS EstimatesBFRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
BFRI Yearly EPS VS EstimatesBFRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BFRI. In the last year negative earnings were reported.
Also next year BFRI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BFRI Price Earnings VS Forward Price EarningsBFRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BFRI Per share dataBFRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

BFRI's earnings are expected to grow with 27.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.55%
EPS Next 3Y27.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BFRI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOFRONTERA INC

NASDAQ:BFRI (5/23/2025, 9:15:34 PM)

After market: 0.64 +0 (+0.03%)

0.6398

-0.03 (-4.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners24.39%
Inst Owner Change-18.2%
Ins Owners7.19%
Ins Owner Change0%
Market Cap5.68M
Analysts82.5
Price Target10.71 (1573.96%)
Short Float %0.6%
Short Ratio0.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-447.73%
Min EPS beat(2)-880.39%
Max EPS beat(2)-15.06%
EPS beat(4)1
Avg EPS beat(4)-235.79%
Min EPS beat(4)-880.39%
Max EPS beat(4)93.63%
EPS beat(8)1
Avg EPS beat(8)-138.27%
EPS beat(12)3
Avg EPS beat(12)-82.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.48%
Min Revenue beat(2)-15.26%
Max Revenue beat(2)-11.71%
Revenue beat(4)0
Avg Revenue beat(4)-15.47%
Min Revenue beat(4)-28.55%
Max Revenue beat(4)-6.36%
Revenue beat(8)1
Avg Revenue beat(8)-10.25%
Revenue beat(12)1
Avg Revenue beat(12)-7.9%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.24%
EPS NY rev (1m)0%
EPS NY rev (3m)10%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 1.28
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-4.16
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS4.21
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -80.35%
ROE -400.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.14%
FCFM N/A
ROA(3y)-51.23%
ROA(5y)-54.01%
ROE(3y)-274.43%
ROE(5y)-268.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y-0.95%
F-Score4
Asset Turnover1.69
Health
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.25%
Cap/Sales 0.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.17
Altman-Z -7.65
F-Score4
WACC21.69%
ROIC/WACCN/A
Cap/Depr(3y)7.65%
Cap/Depr(5y)4.96%
Cap/Sales(3y)0.1%
Cap/Sales(5y)0.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.11%
EPS Next Y81.24%
EPS Next 2Y39.55%
EPS Next 3Y27.72%
EPS Next 5YN/A
Revenue 1Y (TTM)9.53%
Revenue growth 3Y15.69%
Revenue growth 5Y7.35%
Sales Q2Q%18.53%
Revenue Next Year10.36%
Revenue Next 2Y15.16%
Revenue Next 3Y22.03%
Revenue Next 5Y23.53%
EBIT growth 1Y19.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.75%
OCF growth 3YN/A
OCF growth 5YN/A